Apolipoprotein E genotype and Lewy body disease

C. F. Lippa, T. W. Smith, A. M. Saunders, R. Crook, D. Pulaski-Salo, P. Davies, J. Hardy, A. D. Roses, Dennis W Dickson

Research output: Contribution to journalArticle

88 Citations (Scopus)

Abstract

To determine whether apolipoprotein E (APOE) genotype affects neuropathology in Lewy body disease (LBD), we examined 18 cases of LBD that did not have concurrent Alzheimer's disease by the CERAD criteria. We obtained APOE genotypes, determined diffuse β-amyloid plaque (AβP) and Lewy body densities in multiple brain regions, and graded the intensity of CA2-3 ubiquitin-positive neurites, vacuolar change, nigral pathology, amyloid angiopathy, and subpial amyloid deposition. The APOE allele frequencies were as follows: ε2, 0.14 ± 0.07; ε3, 0.64 ± 0.08; and ε4, 0.22 ± 0.03. The mean AβP density was lower in APOE ε3/3 cases (14.5 AβPs per mm2) than in the groups with the APOE ε2 (67.0) or APOE ε4 (46.6) alleles. This difference was due largely to the difference between AβP density in the APOE ε2 group and the APOE ε3/3 group (F = 5.525, p < 0.02). CA2-3 neuritic degeneration was greater in those with the APOE ε4 allele than in those with the APOE ε3/3 genotype (grade = 1.9 ± 1.3 versus 0.938 ± 0.9; Kruskal- Wallis test statistic = 6.962, p < 0.05). These data are consistent with the hypothesis that APOE genotype may affect neuropathology in LBD.

Original languageEnglish (US)
Pages (from-to)97-103
Number of pages7
JournalNeurology
Volume45
Issue number1
StatePublished - 1995
Externally publishedYes

Fingerprint

Lewy Body Disease
Apolipoprotein E3
Apolipoproteins E
Amyloid Plaques
Genotype
Apolipoprotein E2
Apolipoprotein E4
Alleles
Lewy Bodies
Neurites
Substantia Nigra
Ubiquitin
Amyloid
Gene Frequency
Alzheimer Disease
Pathology
Brain
Neuropathology

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Lippa, C. F., Smith, T. W., Saunders, A. M., Crook, R., Pulaski-Salo, D., Davies, P., ... Dickson, D. W. (1995). Apolipoprotein E genotype and Lewy body disease. Neurology, 45(1), 97-103.

Apolipoprotein E genotype and Lewy body disease. / Lippa, C. F.; Smith, T. W.; Saunders, A. M.; Crook, R.; Pulaski-Salo, D.; Davies, P.; Hardy, J.; Roses, A. D.; Dickson, Dennis W.

In: Neurology, Vol. 45, No. 1, 1995, p. 97-103.

Research output: Contribution to journalArticle

Lippa, CF, Smith, TW, Saunders, AM, Crook, R, Pulaski-Salo, D, Davies, P, Hardy, J, Roses, AD & Dickson, DW 1995, 'Apolipoprotein E genotype and Lewy body disease', Neurology, vol. 45, no. 1, pp. 97-103.
Lippa CF, Smith TW, Saunders AM, Crook R, Pulaski-Salo D, Davies P et al. Apolipoprotein E genotype and Lewy body disease. Neurology. 1995;45(1):97-103.
Lippa, C. F. ; Smith, T. W. ; Saunders, A. M. ; Crook, R. ; Pulaski-Salo, D. ; Davies, P. ; Hardy, J. ; Roses, A. D. ; Dickson, Dennis W. / Apolipoprotein E genotype and Lewy body disease. In: Neurology. 1995 ; Vol. 45, No. 1. pp. 97-103.
@article{af144ba9c66a4cfd97907c251e433cfe,
title = "Apolipoprotein E genotype and Lewy body disease",
abstract = "To determine whether apolipoprotein E (APOE) genotype affects neuropathology in Lewy body disease (LBD), we examined 18 cases of LBD that did not have concurrent Alzheimer's disease by the CERAD criteria. We obtained APOE genotypes, determined diffuse β-amyloid plaque (AβP) and Lewy body densities in multiple brain regions, and graded the intensity of CA2-3 ubiquitin-positive neurites, vacuolar change, nigral pathology, amyloid angiopathy, and subpial amyloid deposition. The APOE allele frequencies were as follows: ε2, 0.14 ± 0.07; ε3, 0.64 ± 0.08; and ε4, 0.22 ± 0.03. The mean AβP density was lower in APOE ε3/3 cases (14.5 AβPs per mm2) than in the groups with the APOE ε2 (67.0) or APOE ε4 (46.6) alleles. This difference was due largely to the difference between AβP density in the APOE ε2 group and the APOE ε3/3 group (F = 5.525, p < 0.02). CA2-3 neuritic degeneration was greater in those with the APOE ε4 allele than in those with the APOE ε3/3 genotype (grade = 1.9 ± 1.3 versus 0.938 ± 0.9; Kruskal- Wallis test statistic = 6.962, p < 0.05). These data are consistent with the hypothesis that APOE genotype may affect neuropathology in LBD.",
author = "Lippa, {C. F.} and Smith, {T. W.} and Saunders, {A. M.} and R. Crook and D. Pulaski-Salo and P. Davies and J. Hardy and Roses, {A. D.} and Dickson, {Dennis W}",
year = "1995",
language = "English (US)",
volume = "45",
pages = "97--103",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Apolipoprotein E genotype and Lewy body disease

AU - Lippa, C. F.

AU - Smith, T. W.

AU - Saunders, A. M.

AU - Crook, R.

AU - Pulaski-Salo, D.

AU - Davies, P.

AU - Hardy, J.

AU - Roses, A. D.

AU - Dickson, Dennis W

PY - 1995

Y1 - 1995

N2 - To determine whether apolipoprotein E (APOE) genotype affects neuropathology in Lewy body disease (LBD), we examined 18 cases of LBD that did not have concurrent Alzheimer's disease by the CERAD criteria. We obtained APOE genotypes, determined diffuse β-amyloid plaque (AβP) and Lewy body densities in multiple brain regions, and graded the intensity of CA2-3 ubiquitin-positive neurites, vacuolar change, nigral pathology, amyloid angiopathy, and subpial amyloid deposition. The APOE allele frequencies were as follows: ε2, 0.14 ± 0.07; ε3, 0.64 ± 0.08; and ε4, 0.22 ± 0.03. The mean AβP density was lower in APOE ε3/3 cases (14.5 AβPs per mm2) than in the groups with the APOE ε2 (67.0) or APOE ε4 (46.6) alleles. This difference was due largely to the difference between AβP density in the APOE ε2 group and the APOE ε3/3 group (F = 5.525, p < 0.02). CA2-3 neuritic degeneration was greater in those with the APOE ε4 allele than in those with the APOE ε3/3 genotype (grade = 1.9 ± 1.3 versus 0.938 ± 0.9; Kruskal- Wallis test statistic = 6.962, p < 0.05). These data are consistent with the hypothesis that APOE genotype may affect neuropathology in LBD.

AB - To determine whether apolipoprotein E (APOE) genotype affects neuropathology in Lewy body disease (LBD), we examined 18 cases of LBD that did not have concurrent Alzheimer's disease by the CERAD criteria. We obtained APOE genotypes, determined diffuse β-amyloid plaque (AβP) and Lewy body densities in multiple brain regions, and graded the intensity of CA2-3 ubiquitin-positive neurites, vacuolar change, nigral pathology, amyloid angiopathy, and subpial amyloid deposition. The APOE allele frequencies were as follows: ε2, 0.14 ± 0.07; ε3, 0.64 ± 0.08; and ε4, 0.22 ± 0.03. The mean AβP density was lower in APOE ε3/3 cases (14.5 AβPs per mm2) than in the groups with the APOE ε2 (67.0) or APOE ε4 (46.6) alleles. This difference was due largely to the difference between AβP density in the APOE ε2 group and the APOE ε3/3 group (F = 5.525, p < 0.02). CA2-3 neuritic degeneration was greater in those with the APOE ε4 allele than in those with the APOE ε3/3 genotype (grade = 1.9 ± 1.3 versus 0.938 ± 0.9; Kruskal- Wallis test statistic = 6.962, p < 0.05). These data are consistent with the hypothesis that APOE genotype may affect neuropathology in LBD.

UR - http://www.scopus.com/inward/record.url?scp=0028859880&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028859880&partnerID=8YFLogxK

M3 - Article

VL - 45

SP - 97

EP - 103

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 1

ER -